12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Company News  |  Deals

Cardiome, Merck deal

Cardiome said Merck discontinued development of the oral formulation of atrial fibrillation (AF) product vernakalant. According to Cardiome, Merck based the decision on an assessment of the regulatory environment and projected development timeline. As a result, Cardiome plans to reduce its annual operating cash burn by about half to a...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >